marked.bio

BRAF inhibitor (brain-penetrant) ยท small molecule

claturafenib

2 active trials, targeting BRAF. Not approved for any biomarker on marked.bio yet.

Also known as PF-07799933.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRAF V600E 2 2 Phase 1

Sponsors

Industry sponsors leading active biomarker-selected trials of claturafenib.

  1. Pfizer 2

Trials

2 of 2 trials shown

  1. A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

    Active, not recruiting Phase 1 Pfizer Started 2022Primary completion 2027-08 NCT05355701

    claturafenibbinimetinib FDA EUcetuximab FDA EUmidazolamfluorouracilleucovorinoxaliplatin

    Part 3 (Cohort 4) (BRAF V600E CRC): Minimum of 2 cycles of prior 5-FU based chemotherapy required.

    BRAF V600EMelanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma

  2. A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

    Active, not recruiting Phase 1 Pfizer Started 2022Primary completion 2027-08 NCT05538130

    PF-07799544claturafenib

    Evidence of a BRAF V600 mutation

    BRAF V600EMelanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer